Comparison of the effects of three different anti-fungus drugs on Candida albicans of murine vaginal mucosa

Abstract

To compare the therapeutic effects of three different anti-fungal drugs (i.e., terbinafine, fluconazole and intraconazole) in the treatment of experimental vaginitis caused by Candida albicans (C. albicans) in mice, the fungal vaginitis model was established in female ICR mice by intravaginal inoculation of suspension of C. albicans after the animal had been pretreated with estradiol. Mice were divided at random into different groups and then respectively treated with terbinafine, fluconazole and intraconazole given by gastrogavage. The burden of the fungus in the vaginal lavage fluids in the mice of the different groups was measured dynamically at different time points after the beginning of the drug treatment. The fungal burdens in the vaginal lavage fluids taken at different time points from the mice treated with terbinafine were significantly higher than those taken at corresponding time points from mice treated with fluconazole or itraconazole (P<0.01). The fungal burdens in the vaginal lavage fluids taken from mice 1 week after the beginning of the treatment with terbinafine remained at a relatively high level. A dramatic drop in the fungal burden was noted in the vaginal lavage fluids taken on the 2nd day of the treatment from mice treated with itraconazole or fluconazole group and the fungal burden on the 3rd day of the treatment in these mice were at a very low level, suggesting that fluconazole or itraconazole were highly effective for the treatment. However, the difference in the therapeutic effect between the two drugs was not significant (P>0.05). Itraconazole or fluconazole, but not terbinafine, is very effective for the treatment of fungal vaginitis caused by C. albicans in mice.

Keywords

Candida albicans / vaginal lavage / murine model / terbinafine / itraconazole / fluconazol

References

[1] TheodoreC., KierenA., RaleighA.. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbio Rev, 1998, 11(2): 382

[2] YuanH. W., GuanG. H.. A Clinical and mycological observation of the effects on the treatment of vaginal candidiasis with sporanox and fluconazole. Chin J Derm Venereol, 2003, 17(1): 69-70

[3] PetranyiG., MeingassnerJ. G., MiethH.. Activity of terbinafine in experimental fungal infections of laboratory animals. J Antimicrob Agents Chemother, 1987, 31(10): 1558-1561

[4] PierardG. E., ArreseJ. E., De DonckerP.. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol, 1995, 32(3): 429-35

[5] LiuW., LiR. Y.. The anti-fungal activity in vitro and pharmacokinetics of terbinafine. Chin J New Drugs and Clin Remedies, 2000, 19(7): 8-11

[6] ParazziniF., CintioE., ChianteraV., et al.. Determinants of different candida species infections of the genital tract in women, Sporachrom Study Group. Eur J Obstet Gynecol Rep rod Biol, 2000, 93(2): 141-145